Compare CNDT & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | SIGA |
|---|---|---|
| Founded | 2016 | 1995 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.2M | 223.8M |
| IPO Year | 2016 | 2016 |
| Metric | CNDT | SIGA |
|---|---|---|
| Price | $1.50 | $3.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 915.3K | 549.9K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 19.05% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $3,042,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $170.70 |
| P/E Ratio | ★ N/A | $24.19 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $2.83 |
| 52 Week High | $2.63 | $8.54 |
| Indicator | CNDT | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 45.91 |
| Support Level | $1.31 | $3.02 |
| Resistance Level | $1.62 | $3.32 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 37.50 | 17.19 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.